Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGFR TKI + trastuzumab rezetecan as first-line therapy for EGFR-mutant, HER2-positive advanced NSCLC
ChiCTR2600127858Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jul 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab rezetecan in non-small cell lung cancer (NSCLC), sponsored by West China Hospital of Sichuan University. Primary endpoint: Objective response rate. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600127858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127858.